Tom is clearly in his element as the game combines two of his passions: refereeing and supporting pupils with special ...
Poster presentations from ongoing clinical trials of two core assets, olverembatinib and lisaftoclax, highlight global innovation capabilities in hematologic malignancies ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results